Dystrophin deficiency impairs cell junction formation during embryonic myogenesis.
Elise MozinEmmanuelle MassouridesVirginie MournetasClémence LièvreAudrey BourdonDana L JacksonJonathan S PackerJuyoung SeongCole TrapnellCaroline Le GuinerOumeya AdjaliChristian PinsetDavid L MackJean-Baptiste DupontPublished in: bioRxiv : the preprint server for biology (2024)
Mutations in the DMD gene lead to Duchenne muscular dystrophy, a severe X-linked neuromuscular disorder that manifests itself as young boys acquire motor functions. DMD is typically diagnosed at 2 to 4 years of age, but the absence of dystrophin negatively impacts muscle structure and function before overt symptoms appear in patients, which poses a serious challenge in the optimization of standards of care. In this report, we investigated the early consequences of dystrophin deficiency during skeletal muscle development. We used single-cell transcriptome profiling to characterize the myogenic trajectory of human pluripotent stem cells and showed that DMD cells bifurcate to an alternative branch when they reach the somite stage. Here, dystrophin deficiency was linked to marked dysregulations of cell junction protein families involved in the cell state transitions characteristic of embryonic somitogenesis. Altogether, this work demonstrates that in vitro , dystrophin deficiency has deleterious effects on cell-cell communication during myogenic development, which should be considered in future therapeutic strategies for DMD.
Keyphrases
- duchenne muscular dystrophy
- single cell
- skeletal muscle
- muscular dystrophy
- rna seq
- cell therapy
- healthcare
- gene expression
- type diabetes
- palliative care
- endothelial cells
- pluripotent stem cells
- physical activity
- end stage renal disease
- high resolution
- insulin resistance
- oxidative stress
- adipose tissue
- patient reported outcomes
- replacement therapy
- pain management
- bone marrow
- current status
- small molecule
- drug induced
- protein protein
- atomic force microscopy
- depressive symptoms